Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 264 participants.
Also called NCT03926117
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 264 participants
- Sponsor
- Registry
-
NCT03926117
-
- Other papers using this trial's data
- IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03926117. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-03 (actual); primary completion 2020-06-26 (actual). Results posted on 2023-08-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
- Acronym
- RESCUE
- Condition
- Chronic Kidney Diseases
- Condition
- Inflammation
- Intervention (Biological)
- Ziltivekimab
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03926117- Content hash
56ced556ed4d5164c768a9e87d9eb2f525079dd6eafec8e1da09c21df9b16268